Analyst Thomas Shrader from BTIG maintained a Buy rating on Coya Therapeutics, Inc. and keeping the price target at $15.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thomas Shrader’s rating is based on the promising developments in Coya Therapeutics’ clinical trials, particularly with their COYA-302 treatment. The expansion of the open-label study for FTD patients, which showed cognitive stability in a cohort that typically experiences decline, is a significant positive indicator. This stability in cognitive function among FTD patients is noteworthy, as untreated patients usually show a decline. The company’s efforts to increase the cohort size and the absence of safety issues further de-risk the treatment.
Additionally, the initiation of a key Phase 2 trial for COYA-302 in ALS, which has shown potential to halt disease progression, adds to the positive outlook. The trial’s design and the FDA’s acceptance of the treatment as a new therapeutic, rather than just a combination of existing biosimilars, suggest strong regulatory support. These factors, combined with the potential for COYA-302 to be part of a registrational package, underpin Shrader’s Buy rating for Coya Therapeutics.
In another report released on September 23, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.